Donna McNamara, MD, discusses PARP inhibitors for the treatment of ovarian cancer.
Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, discusses PARP inhibitors for the treatment of ovarian cancer.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More